AN EXAMINATION OF THE EFFECT OF METOCLOPRAMIDE ON PROLIFERATION SIGNAL MOLECULES IN NEWBORN LIVER TISSUE

Öz

Objective: Metoclopramide (MCP) is a drug widely used in nausea and vomiting (in the presence of symptoms / complaints) and recently during lactation period. There are no studies at the molecular level in the literature concerning potential side-effects in the newborn caused by the use of MCP during breastfeeding. The purpose of this study was to investigate the potential proliferative changes in newborn liver tissue caused by MCP.

Material and Method: 18 young adult female Wistar albino rats that had recently given birth, together with their pups, were divided into 3 groups; healthy control, administered a low dose of MCP, and administered a high dose of MCP.

The experiment continued throughout the lactation period. Pups’ hepatic tissues were removed under light microscopy at the end of the 21st day. 5-bromo-2-deoxyuridine (BrdU), Ki-67 and proliferating cell nuclear antigen (PCNA) were used in immunohistochemical staining. BrdU and Ki-67 levels in the tissue homogenate were assessed using the ELISA method.

Results: BrdU, PCNA and Ki-67 immunoreactivities in hepatocytes around the central vein of control group were moderate whereas BrdU, PCNA and Ki-67 immunoreactivities were significantly increased in the low-dose group and in the high-dose MCP groups compared to the control group. In tissue homogenates, Brdu and Ki-67 ELISA levels were observed to be significantly increased in low-dose and high- dose MCP groups compared to the control group.

Conclusion: In our study, increased BrdU, PCNA and Ki-67 immunreactions in livers in both the low- and the high-dose MCP groups show that this agent affected DNA synthesis and it may also cause an excessive proliferation index. 

Anahtar Kelimeler

• Metoclopramide,Liver,BrdU,PCNA,Ki-67

Metoklopramid’in Yenidoğan Karaciğer Dokusunda Proliferasyon Sinyal Molekülleri Üzerine Etkisinin İncelenmesi

Öz

Amaç: Klinikte metoklopramid (MCP) bulantı, kusma (semptomu/yakınması) varlığında ve son yıllarda laktasyon döneminde yaygın olarak kullanılan ilaçtır. MCP’nin emzirme döneminde kullanılmasının yeni doğanda neden olabileceği yan etkilerle ilgili literatürde moleküler düzeyde bir çalışma bulunmamaktadır. Çalışmamızda MCP’nin yenidoğan karaciğer dokusunda neden olabileceği proliferatif değişikliklerin incelenmesi amaçlanmıştır.

Gereç ve Yöntem: Çalışmada 18 adet dişi Wistar-albino yeni doğum yapmış sıçanlar yavruları ile birlikte 3 gruba ayrıldı. Sağlıklı kontrol, düşük doz MCP uygulanan grup, yüksek doz MCP uygulanan grup. Deney laktasyon dönemi boyunca devam etti ve 21 gün sonunda yavruların karaciğer dokusunda immunohistokimyasal boyama ile 5-Bromo-2-Deoksiuridin (BrdU), Ki-67 ve prolifere hücre nükleer antigeni (PCNA); doku homojenatında ELISA ile  BrdU ve Ki-67 düzeyleri değerlendirildi.

Bulgular: Kontrol grubunun santral ven çevresindeki hepatositlerde BrdU, PCNA ve Ki-67 immunreaktiviteleri orta şiddette iken; düşük ve yüksek doz metoklopramid gruplarında kontrole göre istatistiksel anlamlı arttığı saptandı. Doku homojenatları BrdU ve Ki-67 düzeylerinde, hem düşük hem de yüksek doz MCP gruplarında kontrole göre istatistiksel olarak anlamlı artış gözlendi.

Sonuç: Çalışmamızda hem düşük hem de yüksek doz MCP gruplarında, BrdU, PCNA ve Ki-67 immunreaksiyonun artması bu ajanın, hücrede DNA sentezini etkilediğini göstermektedir. Bu da aşırı proliferasyon indeksine neden olabilmektedir

Anahtar Kelimeler

• Metoklopramid,Karaciğer,BrdU,PCNA,Ki-67

Kaynakça

1. Kauppila A, Arvela P, Koivisto M, Kivinen S, Ylikorkala O, Pelkonen O. Metoclopramide and breast feeding: transfer into milk and the newborn. Eur J Clin Pharmacol 1983;25:819-23.
2. Oddy WH. Breastfeeding, Childhood Asthma, and Allergic Disease. Ann Nutr Metab 2017;70 Suppl 2:26-36.
3. Zingler E, Amato AA, Zanatta A, Vogt MF, Wanderley MD, Mariani Neto C,Zaconeta AM. Lactation Induction in a Commissioned Mother by Surrogacy: Effects on Prolactin
4. Levels, Milk Secretion and Mother Satisfaction. Rev Bras Ginecol Obstet 2017;39:86-89.
5. Tianyi FL, Agbor VN, Njim T. Metoclopramide induced acute dystonic reaction: a case report. BMC Res Notes 2017;10:32.
6. Fife S, Gill P, Hopkins M, Angello C, Boswell S, Nelson KM. Metoclopramide to augment lactation, does it work? A randomized trial. J Matern Fetal Neonatal Med 2011;24:1317-20.
7. Bazzano AN, Hofer R, Thibeau S, Gillispie V, Jacobs M, Theall KP.A Review of Herbal and Pharmaceutical Galactagogues for Breast-Feeding. Ochsner J 2016;16:511-524
8. Forinash AB, Yancey AM, Barnes KN, Myles TD The use of galactogogues in the breastfeeding mother. Ann Pharmacother 2012;46:1392-404.

9. Shamir R. The Benefits of Breast Feeding. Nestle Nutr Inst Workshop Ser 2016;86:67-76.
10. Gabay MP. Galactogogues: medications that induce lactation. J Hum Lact 2002;18:274-9.
11. Jarrar D, Wang P, Song GY, Knöferl MW, Cioffi WG, Bland KI, Chaudry IH. Metoclopramide: a novel adjunct for improving cardiac and hepatocellular functions after trauma-hemorrhage. Am J Physiol Endocrinol Metab 2000;278:E90-5.
12. Ingram J, Taylor H, Churchill C, Pike A, Greenwood RMetoclopramide or domperidone for increasing maternal breast milk output: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2012;97:F241-5.
13. Ehrenkranz RA, Ackerman BA. Metoclopramide effect on faltering milk production by mothers of premature infants. Pediatrics 1986;78:614-620.
14. Kauppila A, Kivinen S, Ylikorkala O. A dose response relation between improved lactation and metoclopramide. Lancet 1981;1:1175-1177.
15. Brown TE, Fernandes PA, Grant LJ, Hutsul JA, McCoshen JA. Effect of parity on pituitary prolactin response to metoclopramide and domperidone: implications for the enhancement of lactation. J Soc Gynecol Investig 2000;7:65-69.
16. Zuppa AA, Sindico P, Orchi C, Carducci C, Cardiello V, Romagnoli C. Safety and efficacy of galactogogues: substances that induce, maintain and increase breast milk production. J Pharm Pharm Sci 2010;13:162-174.
17. Iatropoulos MJ, Williams GM. Proliferation markers. Exp Toxicol Pathol 1996;48:175-81.
18. Assy N, Minuk GYLiver regeneration: methods for monitoring and their applications. J Hepatol 1997;26:945-52
19. Gürgen SG, Sayın O, Cetin F, Tuç Yücel A. Transcutaneous electrical nerve stimulation (TENS) accelerates cutaneous wound healing and inhibits pro-inflammatory cytokines. Inflammation 2014;37:775-84.
20. De Gezelle H, Ooghe W, Thiery M, Dhont M. Metoclopramide and breast milk. Eur J Obstet Gynecol Reprod Biol 1983;15: 31-36.
21. Hibbs AM, Lorch SA. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics 2006;118:746-52.
22. O'Donnell A, McParlin C, Robson SC, et al. Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review and economic assessment. Health Technol Assess 2016;20:1-268.
23. Carlisle JB, Stevenson CA. Drugs for preventing postoperative nausea and vomiting.Cochrane Database Syst Rev. 2006;(3):CD004125.
24. Rao AS, Camilleri M.Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther 2010;31:11-9.
25. Espinós JJ, Vanrell C, Gich I, Urgell E, Calaf J. Pituitary response profile following metoclopramide administration in women with different forms of hyperprolactinemia. Gynecol Endocrinol. 2017;33:148-151.
26. Igata R, Hori H, Atake K, Katsuki A, Nakamura J. Adding metoclopramide to paroxetine induced extrapyramidal symptoms and hyperprolactinemia in a depressed woman: a case report. Neuropsychiatr Dis Treat 2016;12:2279-81.
27. Moos DD, Hansen DJ. Metoclopramide and extrapyramidal symptoms: a case report. J Perianesth Nurs 2008;23:292-9.
28. Lewis PJ, Devenish C, Kahn C. Controlled trial of metoclopramide in the initiation of breast feeding. Br J Clin Pharmacol 1980;9:217-219.
29. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC. Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs 1983;25:451-494.
30. Sankaran K, Yeboah E, Bingham WT, Ninan A. Use of metoclopramide in preterm infants. Dev Pharmacol Ther 1982;5: 114-119.
31. Briggs GG, Freeman RK, Yaffe SJ, eds. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. Tenth Edition. Philadelphia: Walters Kluwer/Lippincott Williams and Wilkins Health, 2015.
32. Kauppila A, Kivinen S, Ylikorkala O. Metoclopramide increases PRL release and milk secretion in puerperium without stimulating the secretion of thyrotropin and thyroid hormones. J Clin Endocrinol Metab 1981;52:436-439.
33. Gupta AP, Gupta PK. Metoclopramide as a lactogogue. Clin Pediatr 1985;24:269-272.
34. Cervelló I, Martínez-Conejero J, Horcajadas J, Pellicer A, Simón C. Identification, characterization and co-localization of label-retaining cell population in mouse endometrium with typical undifferentiated markers. Hum Reprod 2006;22:45–51.
35. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22.
36. Huisman MA, De Heer E, Grote JJ. Cholesteatoma epithelium is characterized by increased expression of Ki-67, p53 and p21, with minimal apoptosis. Acta Otolaryngol 2003;123:377-82.